* IGM Biosciences Inc is expected to show a fall in quarterly revenue when it reports results on November 11 (estimated) for the period ending September 30 2024
* The Mountain View California-based company is expected to report a 47.5% decrease in revenue to $267.22 thousand from $509 thousand a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
* LSEG's mean analyst estimate for IGM Biosciences Inc is for a loss of 80 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for IGM Biosciences Inc is $17.50, above its last closing price of $14.37.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.02 -0.04 -0.79 Missed -1,991
.1
Jan. 1 2024 -0.83 -0.83 -0.83 Met 0.2
Dec. 31 2023 -0.96 -1.03 -1.01 Beat 2.2
Sep. 30 2023 -1.18 -1.21 -1.04 Beat 14.3
Jun. -1.44 -1.43 -1.43 Met 0.3
30 2023
Mar. 31 2023 -1.34 -1.36 -1.33 Beat 2.5
Dec. 31 2022 -1.25 -1.19 Beat 4.5
Sep. 30 2022 -1.44 -1.43 -1.32 Beat 7.5
This summary was machine generated November 8 at 15:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments